Clinical Trials Logo

Clinical Trial Summary

Cerebral Palsy is the most common cause of severe physical disability in childhood and may present difficulties and limitations that will have an impact on their independence and integration in all social areas. Within interventions aiming to manage CP Whole-Body Vibration (WBV) has shown some benefits such as reducing spasticity or improving strength and functionality of the lower limbs. The aim of this study is to assess the effectiveness on motor function and spasticity of the lower limbs by adding an intervention with WBV to an evidence-based multimodal physiotherapy treatment in children with CP.


Clinical Trial Description

Cerebral Palsy is the most common cause of severe physical disability in childhood (1.5 - 3 cases per thousand live births) and may or may not be accompanied by intellectual, sensory, communication deficits and epileptic syndromes depending on the brain region affected. The most frequent form of presentation is spastic cerebral palsy, characterized by atypical motor development, abnormal movement or posture, hyperreflexia, and increased muscle tone. These difficulties and limitations will have an impact on their independence and integration in all social areas. The use of Whole-Body Vibration (WBV) to reduce spasticity of the lower limb and thereby improve functionality has been used for more than a decade showing some benefits such as reducing spasticity or improving strength and functionality of the lower limbs. The purpose of this randomized controlled trial is to assess the effectiveness on motor function and spasticity of the lower limbs by adding an intervention with WBV to an evidence-based multimodal physiotherapy treatment in children with CP. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06330311
Study type Interventional
Source Universidad Complutense de Madrid
Contact
Status Active, not recruiting
Phase N/A
Start date March 29, 2024
Completion date September 29, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT02907775 - Multi-channel Stimulation for Post Stroke Spasticity (MUSTS) N/A
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Active, not recruiting NCT03521076 - Randomized Controlled Trial of Virtual Reality N/A
Completed NCT03080454 - The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke Phase 1/Phase 2
Completed NCT02546999 - Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Phase 4
Active, not recruiting NCT01041157 - Botulinum Toxin Injection Efficiency Phase 1
Completed NCT00535938 - MDs on Botox Utility (MOBILITY) N/A
Terminated NCT00531466 - Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury Phase 2
Terminated NCT00532532 - Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis Phase 2
Completed NCT05546190 - A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT01603628 - BOTOX® Treatment in Pediatric Lower Limb Spasticity Phase 3
Completed NCT05510726 - Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity
Not yet recruiting NCT04378946 - Error Augmentation Motor Learning Training Approach in Stroke Patients N/A
Completed NCT01603615 - BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase 3
Completed NCT01251380 - Dysport® Pediatric Lower Limb Spasticity Follow-on Study Phase 3
Completed NCT00549783 - BOTOX® Economic Spasticity Trial (BEST) Phase 4
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT00076687 - Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function Phase 2